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Abstract
Background: Late-onset Pompe disease is a rare genetic neuromuscular disorder caused by a primary deficiency of
α-glucosidase and the associated accumulation of glycogen in lysosomal vacuoles. The deficiency of α-glucosidase
can often be detected using an inexpensive and readily accessible dried blood spot test when Pompe disease is
suspected. Like several neuromuscular disorders, Pompe disease typically presents with progressive weakness of
limb-girdle muscles and respiratory insufficiency. Due to the phenotypic heterogeneity of these disorders, however,
it is often difficult for clinicians to reach a diagnosis for patients with Pompe disease. Six hundred and six patients
from a European population were recruited onto our study. Inclusion criteria stipulated that index cases must
present with limb-girdle weakness or elevated serum creatine kinase activity. Whole exome sequencing with at
least 250 ng DNA was completed using an Illumina exome capture and a 38 Mb baited target. A panel of 169
candidate genes for limb-girdle weakness was analysed for disease-causing variants.
Results: A total of 35 variants within GAA were detected. Ten distinct variants in eight unrelated index cases
(and four siblings not sequenced in our study) were considered disease-causing, with the patients presenting
with heterogeneous phenotypes. The eight unrelated individuals were compound heterozygotes for two
variants. Six patients carried the intronic splice site c.-13 T > G transversion and two of the six patients also
carried the exonic p.Glu176ArgfsTer45 frameshift. Four of the ten variants were novel in their association with
Pompe disease.
Conclusions: Here, we highlight the advantage of using whole exome sequencing as a tool for detecting,
diagnosing and treating patients with rare, clinically variable genetic disorders.
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Background
Pompe disease (OMIM 232300) is a rare autosomal reces-
sive lysosomal storage disorder that most prominently af-
fects muscle tissue. The disease is generally classified into
two broad categories: an infantile- and a late- onset form.
Patients with the infantile-onset form of the disease typic-
ally present with generalised weakness, hypotonia, respira-
tory distress and cardiomyopathy, and without intervention
do not survive beyond 12 months of age [1]. Late-onset
Pompe disease is more clinically heterogeneous [2], yet
often displays a central characteristic manifestation of a
slowly progressive proximal myopathy. This occurs with re-
spiratory weakness and elevated serum creatine kinase
activity, while there is normally no clinically relevant
cardiac involvement [3]. Estimates of the frequency of
all cases of Pompe disease vary, but have been re-
ported to be as high as approximately 1:40,000 [4, 5].
The late-onset classification of the disease is even
rarer at a frequency of 1:57,000 [5].
The varied clinical spectrum can be attributed to
the many different genetic mutations that are associ-
ated with Pompe disease; to date, the associations of
over 522 variants have been reported and collated by
the Pompe Disease Mutation Database [6]. Such mu-
tations occur within the GAA gene and result in a
deficiency of the encoded lysosomal enzyme, acid α-
glucosidase, which is essential for glycogen hydrolysis.
The accumulation of glycogen within lysosomes sub-
sequently impairs the correct functioning of the or-
ganelles and the affected tissue, primarily skeletal and
cardiac muscle [7], and results in the clinical presen-
tation of Pompe disease.
Considering the rarity and variability of the disorder, a
correct clinical diagnosis is often difficult to achieve, and
so many patients are therefore not treated with an effica-
cious disease-modifying enzyme replacement therapy
(ERT) in a timely manner. ERT, a recombinant human
acid α-glucosidase termed alglucosidase alfa, has been
reported to extend survival in infantile Pompe disease
[8] and ameliorate disease progression of the late-onset
form [9]. As prompt diagnosis and treatment is benefi-
cial to patient survival [10], a more robust investigatory
approach is required to detect and diagnose affected in-
dividuals in the early stages of the disease.
Exome sequencing is a useful tool to interrogate the
proportion of the genome that is enriched for functional
coding variants, specifically those that are able to disrupt
protein structure and function [11]. This unbiased ana-
lysis enables the detection of distinct mutations in pa-
tients with overlapping phenotypes, overall expanding
existing genotype-phenotype correlations. Exome se-
quencing, therefore, has the benefit of furthering the un-
derstanding of disease pathology, offering accurate
diagnoses where the traditional methodologies of clinical
examinations failed to do so, and in some cases also en-
abling a prompt intervention in the disease progression.
The MYO-SEQ project was established in 2014 and
aimed to use whole exome sequencing to (i) contribute to
the diagnostic pathway of patients affected by limb-girdle
muscular weakness, (ii) improve the diagnostic awareness
of rare genetic neuromuscular diseases, and (iii) speed up
the integration of next-generation sequencing technologies
into healthcare [12]. We screened 606 patients with unex-
plained limb-girdle weakness for potentially pathogenic
variants in 169 genes that are known to be associated with
muscle disease. Here, we report on the characterisation of
twelve European patients (eight index cases and four sib-
lings) who harboured disease-associated variants within
GAA as identified through the MYO-SEQ project.
Methods
Patient recruitment and inclusion criteria for whole
exome sequencing
Ethical approval was granted by the Newcastle and
North Tyneside research ethics committee (REC refer-
ence number 09/H0906/28) and by the local ethical
committees of the participating centres. A standardised
form for collecting detailed phenotypic information was
created using the PhenoTips online software tool [13]:
this was completed by the referring clinician for each pa-
tient enrolled onto the project. Informed written consent
was given by the patients, who were anonymised by the
collaborating centres by using unique MYO-SEQ patient
identification codes. The fundamental requirement for
inclusion in the project was that of unexplained limb-
girdle muscle weakness and/or elevated serum creatine
kinase activity.
Lysis of whole blood cells
Blood samples were taken from each patient using an
EDTA Vacutainer® Safety-Lok™ system (BD Biosciences,
UK). Two buffers were prepared prior to cell lysis: Buffer A
(pH 8.0; 10 mM Tris-HCl, 320 mM sucrose, 5 mM MgCl2,
1% Triton X-100) and Buffer B (pH 8.0; 400 mM Tris-HCl,
0.5 M EDTA pH 8.0, 150 mM NaCl, 1% SDS). Five millili-
tres (ml) of whole blood was mixed with 40 ml of Buffer A
for 4 minutes (min) at room temperature before centrifuga-
tion at 3000 revolutions per minute (rpm) for 10 min. The
cell pellet was resuspended in 20 ml Buffer A before the
mixing and centrifugation steps repeated once more. The
pellet was resuspended in 2 ml Buffer B, mixed for 10 min
at room temperature with 500 μl sodium perchlorate, and
incubated at 65 °C for 25 min with regular vortexing.
Nucleic acid extraction from lysed whole blood cells
The preparation of lysed cells was mixed for 10 min at
room temperature with 2 ml ice cold chloroform followed
by centrifugation at 4 °C for 10 min at 3000 rpm. The
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supernatant was mixed by gentle inversion with 6 ml 98%
ethanol, and the visible DNA precipitate transferred to
500 μl 70% ethanol. The sample was centrifuged for 1 min
at 14,000 rpm and the pelleted DNA precipitate air dried
at room temperature. The DNA was dissolved in 300 μl
TE buffer (10 mM Tris base, 1 mM EDTA [pH 8.0]) over-
night at 4 °C followed by a final 1 h incubation at 54 °C.
The nucleic acid was quantified using a NanoDrop™ 8000
spectrophotometer (ThermoScientific, Surrey, UK) and
stored at -20 °C.
Whole exome sequencing
Whole exome sequencing and data processing [14] were
performed by the Genomics Platform at the Broad Insti-
tute of Harvard and MIT (Broad Institute, Cambridge,
MA, USA). Briefly, whole exome sequencing was per-
formed on DNA samples (>250 ng at >2 ng/μl) using
Illumina exome capture (38 Mb target). Our exome se-
quencing pipeline included sample plating, library prep-
aration (2-plexing of samples per hybridisation), hybrid
capture, sequencing (76 bp paired reads), sample identi-
fication, quality control check, and data storage. Our hy-
brid selection libraries cover >80% of targets at 20× and
an overall mean target coverage of >80×, while GAA had
mean coverage of 87.1×. The exome sequencing data
was de-multiplexed and each sample’s sequence data
were aggregated into a single Picard BAM file. The data
were processed through a pipeline based on Picard using
base quality score recalibration and local alignment at
known insertions/deletions. The reads were mapped to
the human genome build 37 (hg19) using the Burrows-
Wheeler Aligner. Single nucleotide polymorphisms and
insertions/deletions were jointly called using the Gen-
ome Analysis Toolkit HaplotypeCaller package v3.1 [15–
17]. Default filters were applied to the variant calls using
the Genome Analysis Toolkit Variant Quality Score Re-
calibration approach, and the variants were annotated
using Variant Effect Predictor.
Analysis of whole exome sequencing data
The variant call set was uploaded onto the Broad Institute
of Harvard and MIT’s seqr platform. The biological rele-
vance of the variants identified within GAA was determined
by considering the (i) population frequency detailed by the
Exome Aggregation Consortium (ExAC) of the Broad Insti-
tute of Harvard and MIT [14], (ii) deleteriousness of the
variant predicted by PolyPhen-2 [18], SIFT [19], Mutation-
Taster2 [20], and FATHMM [21], and (iii) ClinVar reports
of pathogenicity [22] and published literature.
Reporting of GAA variants and confirmation of Pompe
disease
The detected variants were matched to the patient’s
phenotype and those that were most likely to be disease-
causing were reported back to the referring clinician. A
positive diagnosis of Pompe disease was sought by the
clinicians by quantifying α-glucosidase activity using
dried blood spots (DBS) or fibroblasts, and/or perform-
ing Sanger sequencing to independently confirm the de-
tected variants.
Results
Detection of variants within GAA
Of the 606 patients whose exomes were sequenced, 268
(44%) were female and 338 (56%) were male; their ages
ranged from 4 years to 88 years (mean 40.1 years, me-
dian 40.0 years). In the first instance, a search of the
GAA exons of all 606 patients was performed to identify
those who harboured rare (< 1%) coding variants. A total
of 34 distinct coding variants were identified (Table 1) in
35 unrelated individuals. Of these variants, ten were syn-
onymous and so were not considered potentially disease-
causing. Of the remaining 24 variants, 16 were missense,
three were frameshift, one created a stop codon and four
affected the splice site regions of the gene. Eight of the 24
variants were novel, meaning they did not occur in the
ExAC v3 control population of over 60,000 unrelated
healthy individuals [14]. Finally, six of the 24 variants,
three of which were novel, have been previously listed in
the Pompe Disease Mutation Database [6] and so have a
known association with the disease.
Since there were no homozygous coding variants that
could in isolation account for the phenotype of the pa-
tients, and in fact an extremely common GAA mutation
in Pompe disease is intronic [23], we extended the search
to include flanking regions that were captured by the ex-
ome sequencing. As a result, the common intronic c.-32-
13 T >G variant was detected and was considered poten-
tially pathogenic when in combination with either a cod-
ing or an already reported pathogenic variant (Table 1).
Analysis of GAA variants and classification of disease-
causing mutations
It was next necessary to interrogate the 22 patients that
accounted for the 24 coding and one intronic GAA vari-
ants that were potentially disease-causing. Patients 3, 5,
7, 8, 18, and 32 all harboured the intronic c.-32-13 T > G
variant in addition to a coding variant within GAA,
which generated a compound heterozygous haplotype
that could be responsible for α-glucosidase deficiency.
Patients 17 and 35 carried two coding variants: patient
17 carried one frameshift and one missense, both of
which were absent in the ExAC control population [14],
and patient 35 harboured two missense variants, one of
which was absent in the ExAC population [14] and the
other previously reported in the Pompe Disease Muta-
tion Database [6]. Patient 21 harboured a missense vari-
ant that was predicted to be damaging, while a second
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variant affected a splice site, neither of which were novel:
this was not considered a likely cause of the patient’s
phenotype. The ten variants considered disease-causing
are detailed in Fig. 1, and the summarised patient infor-
mation is detailed in Table 2. The remaining 14 patients
only carried one heterozygous variant, meaning it was
highly probable that α-glucosidase deficiency was not
the cause of their disorder.
GAA variants were associated with a highly varied clinical
spectrum
There was a wide variability in the presenting symptoms
between each of the eight patients, despite the variants
all affecting the same gene. This was particularly notable
for patients 18 and 32 who both carried the same GAA
variants, c.525delT and c.-32-13 T > G. Patient 18 had a
slowly progressive phenotype after the onset of symp-
toms in her fifth decade of life, displaying proximal
muscle weakness and a serum creatine kinase activity of
599 U/L (N < 170 U/L). The patient also showed a myo-
pathic electromyogram (EMG). A muscle biopsy was in-
dicative of a myofibrillar myopathy, with numerous
vacuolated, degenerated and atrophic fibres confirmed
by NADH-tetrazolium reductase staining. The periphery
of the vacuoles had an abnormal immunoreactivity for
desmin and p62. The fibre type proportions and distri-
butions appeared normal; however an ultrastructural
examination displayed Z-band streaming with an accu-
mulation of granular material. Glycogen accumulation in
the vacuoles was noted, but the overall appearance was
not suggestive of a glycogenosis, while a DBS test re-
vealed α-glucosidase activity to be within the normal to
lower ranges. Following our report of the GAA variants
to the collaborating centre, this patient has since been
referred for ERT.
In contrast, patient 32 had a non-progressive pheno-
type after the onset of his symptoms in childhood. His
serum creatine kinase activity was persistently elevated;
when first investigated at age 15 years of age it was
662 U/L (N < 190 U/L). The patient had no cardiac in-
volvement nor exhibited extreme respiratory distress, al-
though a 13% reduction between sitting and supine
forced vital capacity was observed. The patient described
only slight dyspnoea following physical exertion, but
otherwise considered himself healthy. Both a muscle bi-
opsy and an EMG were mildly myopathic. A DBS test
displayed reduced enzymatic activity, while Sanger se-
quencing of the variants confirmed Pompe disease. Add-
itionally, the reduction in α-glucosidase activity and
carriage of the variants were confirmed in his two sib-
lings. Both, however, are currently asymptomatic with el-
evated serum creatine kinase levels only (563 U/L and
1331 U/L for his 10 year old sister and 23 year old
brother, respectively). ERT is scheduled for the index
case, and all three of these family members will be
closely monitored.
A further example to highlight the varied clinical pre-
sentations was seen in patient 3. This individual dis-
played a slowly progressive proximal lower limb and
axial weakness with the onset of symptoms in his third
decade of life. There was no respiratory insufficiency
and an EMG showed no abnormalities. Despite normal
cardiac function, the patient was previously diagnosed
with Brugada syndrome, a genetic cause for abnormal
electrocardiogram findings that are associated with an
increased risk of sudden cardiac death. Serum creatine
kinase activity was measured at 1729 U/L (N < 190 U/L).
The two GAA variants were confirmed by the collaborat-
ing centre using Sanger sequencing, while a reduced en-
zymatic activity was confirmed using a DBS test. Since
the diagnosis of Pompe disease in the index case, he was
started on ERT and his asymptomatic brother, with only
an elevated serum creatine kinase activity, was also diag-
nosed with the disease. This clearly demonstrates that
Fig. 1 Ten distinct variants within GAA were identified as disease-causing. One variant was intronic and nine were exonic. Six patients were
heterozygous for the intronic c.-32-13 T > G variant in addition to an exonic variant and two patients were heterozygous for two exonic variants
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related individuals diagnosed with the same genetic dis-
ease can present with a varied phenotypic spectrum.
Patient 5 initially presented with back pain and elevated
serum creatine kinase levels (1500 U/L), and retrospect-
ively recognised mild proximal upper limb weakness when
raising a load. The disease course progressed over the fol-
lowing nine years, with asymmetrical proximal weakness
becoming more obvious. At hospitalisation, a reduced en-
zyme activity was observed in the patient and also in his
daughter. Only two patients were not started on ERT: pa-
tient 7 lives in another country to where she was enrolled
onto the project and patient 8 is in her mid-70s and is not
ambulant.
Comparison of compound heterozygous patients at two
exonic GAA variants
Patient 17 harboured two novel coding variants within
GAA, c.1192delC and c.2716G > A, neither of which have
been listed in the Pompe Disease Mutation Database [6].
Importantly, however, c.1192delC results in a frameshift
mutation at the same position as a reported pathogenic
duplication [24]. The patient presented with progressive
proximal muscle weakness, pain and fatigability in his
fourth decade of life, but with normal levels of serum cre-
atine kinase activity. He also displayed weakness of the
back muscles and had notable respiratory dysfunction: his
forced vital capacity was reduced to 2.41 (47% predicted
normal value) in the sitting and to 2.0 l (39% predicted
normal value) in the lying position. An EMG detected
mild myopathic changes and the muscle biopsy showed
increased variability in fibre diameter without any abnor-
mal glycogen accumulation. The patient had two DBS
tests: the first suggested a reduction in α-glucosidase ac-
tivity, while the second detected normal levels of enzyme
activity. A subsequent analysis of α-glucosidase in lym-
phocytes and fibroblasts revealed borderline and low nor-
mal activity, respectively. It is likely, therefore, that
c.2716G >A may be a weaker mutation, and so only
slightly affects enzyme activity. The variants were inde-
pendently confirmed by the collaborating centre before
ERT was initiated for the patient. At the start of ERT, the
patient achieved 100 m in a six minute walk test, which
marginally increased to 105 m after 9 months of alternat-
ing weekly administrations of 20 mg/kg Myozyme®. Mea-
sures of respiratory muscle strength similarly remained
unchanged; from a vital capacity of 45% to 47%, a maximal
inspiratory pressure of 5.6 kPa to 5.8 kPa and a maximal
expiratory pressure of 6.1 kPa to 5.4 kPa. The referring
clinician observed a negligible effect on muscle pain and
weakness – as might be expected with borderline enzym-
atic activities treated over such a short period – and so
the patient was withdrawn from the regime. Eighteen
months after ERT cessation, the status of the patient
remained stable with a six minute walk test of 95 m.
Similarly, patient 35 carried two coding variants within
GAA: c.569G > A and c.2020C > G, with the former
recognised in the Pompe Disease Mutation Database [6]
and the latter completely absent in the ExAC unaffected
control population [14]. The patient presented in his
fourth decade of life with rapidly progressive proximal
lower limb weakness, difficulty in ascending stairs and
an inability stand unaided from a supine position. His
older sister is also affected with an earlier onset of her
symptoms at 21 years of age. The patient now has scoli-
osis, fatigability, paraspinal muscle atrophy, and prox-
imal upper limb atrophy and weakness. Paraclinical
examinations revealed a myopathic EMG, a dystrophic
biopsy and mildly elevated serum creatine kinase levels.
A calpain deficiency was detected through immunoblot
analysis and could be attributed to two heterozygous
CAPN3 variants (p.Gly333Asp [c.998G > A] and
p.Ala726Ser [c.2176G > T]). This suggested that the pa-
tient is likely to be affected by both LGMD2A and
Pompe disease. The two GAA variants were independ-
ently confirmed and in contrast to patient 17, the unam-
biguous absence of glycogen was confirmed in the
patient and in his sister. ERT is now being administered
to both individuals.
Discussion
Whole exome sequencing is emerging as an affordable
technology to investigate rare, monogenic diseases. Cod-
ing and functional regions account for only 1% of the
entire human genome, yet harbour 85% of known
disease-causing variants [25]. On this basis, we se-
quenced the exomes of a cohort of 606 patients with un-
explained limb-girdle weakness. We examined a panel of
169 genes that were known to be associated with muscle
diseases with Mendelian patterns of inheritance in a
large cohort of European patients with unexplained
limb-girdle weakness. Overall, we identified eight unre-
lated index cases and four siblings that had compound
heterozygous mutations in GAA: these patients were
likely to be affected by Pompe disease, a rare lysosomal
storage disorder that is commonly characterised by
proximal muscle weakness [2]. The remaining 168 genes
are currently under analysis and we are yielding similarly
positive results for many other muscle diseases; so far
the overall diagnostic rate for the project is 49%.
We have shown that next-generation sequencing is ad-
vantageous in the healthcare and diagnosis of patients
suffering from unexplained limb-girdle muscle weakness.
Other studies have shown similar benefits [26], achieving
a correct diagnosis for patients with overlapping, and
therefore indistinguishable, clinical phenotypes [27]. In a
recent publication that interrogated the exomes of 504
patients of European descent, variants in GAA were con-
sidered pathogenic in 10 patients (1.9% of the cohort)
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[28]. This is highly comparable to the 12 patients with
GAA variants detected by MYO-SEQ. While such an ap-
proach helps better understand rare neuromuscular dis-
orders, it was especially important in this study for the
patients that suffered from treatable conditions such as
Pompe disease. It is most beneficial to the affected indi-
viduals that ERT is initiated as soon as possible as the
therapy acts to ameliorate disease progression [29]. Des-
pite DBS tests being widely available, inexpensive and
sensitive to changes specifically in α-glucosidase activity
[30], they can sometimes fail to robustly detect subtle
changes in enzyme activity. This is considered more
common in later onset forms of the disorder, where the
level of enzyme activity may be proportional to the age
of onset [29]. Although reduced enzymatic activity was
detected by DBS tests in 7.6% of patients in a cohort
presenting with elevated serum creatine kinase and/or
limb-girdle muscular weakness, late-onset Pompe dis-
ease was only confirmed in 2.4% of the patients [31].
DBS tests may therefore be inconclusive for many pa-
tients with a proximal muscle weakness phenotype. Such
a discrepancy was exemplified in the clinical assessment
of patient 18 who presented with the onset of symptoms
in her fifth decade of life and normal to slightly lower α-
glucosidase activity. Despite the borderline enzymatic ac-
tivity levels detected, the individual was subsequently
found to carry two reported pathogenic GAA variants.
Therefore, exome sequencing offers an alternative, ac-
curate and reliable methodology for rare disease diagno-
sis where traditional detection techniques may not be as
efficient. We suggest that DBS should still be used as a
first-tier diagnostic step when Pompe disease is sus-
pected, however, diagnostic yields are influenced by the
type and level of pre-screening, and so it is inaccurate to
compare the outcomes of different approaches.
As Pompe disease is an autosomal recessive disorder,
single heterozygous variants are unlikely to result in a
depletion of α-glucosidase activity that is sufficient to
cause a clinical phenotype. Accordingly, it has been
found that many affected individuals carry compound
heterozygous mutations rather than isolated heterozy-
gous or homozygous variants [32–35]. This immediately
allowed our analysis to be focussed on the patients
that harboured two variants: of course, a second vari-
ant may still be missed if it resides in a deep intronic
region not covered by WES. Nevertheless, of the nine
compound heterozygous patients that we identified,
we considered eight to carry variants that were suffi-
ciently severe to cause Pompe disease. Four of the
ten likely pathogenic variants that were identified in
this study had never been previously reported in
Pompe disease [6] and did not occur in the ExAC
control population [14]. These variants that we
present here – c.1192delC, c.2020C > G, c.2051C > G
and c.2716G > A – are therefore novel in the under-
standing of Pompe disease.
As would be expected based on previous findings
[23, 35], the intronic c.-32-13 T > G variant was the
most frequent in this largely Caucasian population, and
occurred in six compound heterozygous index cases. It is
therefore essential that analyses of GAA gene sequences
should be extended to flanking regions in order to capture
such pathogenic intronic variants. This variant affects a
splice site of the gene, and so the result is the production
of alternative transcript isoforms and low levels of α-
glucosidase activity. This can give rise to the typical
spectrum of Pompe disease phenotypes depending on the
haplotype it occurs in [36]. Overall, the specific mutations,
their haplotypes, and their genetic positions are all key in
determining enzymatic activity and thus, the clinical
phenotype of patients affected by Pompe disease.
Conclusions
In summary, we have identified twelve individuals (eight
index cases and four siblings) with compound heterozy-
gous mutations in the GAA gene; four of the ten variants
have not been previously reported. This study has ex-
panded the existing genotype-phenotype correlations;
aiding a deeper understanding of Pompe disease, the
underlying genetic variations and the associated varied
clinical presentation. We have shown the advantage of
using next-generation sequencing in the diagnosis of a
rare, treatable neuromuscular condition. As a result, pa-
tients have benefitted from a swifter administration of
appropriate disease managements. Our data suggest that
exome sequencing is a reliable and accurate diagnostic
tool and is able to detect pathogenic variants in patients
for whom traditional clinical methodologies have failed.
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